Cowppli-Bony Anne, Colonna Marc, Ligier Karine, Jooste Valérie, Defossez Gautier, Monnereau Alain
Registre des tumeurs de Loire-Atlantique et Vendée, 50, route de St-Sébastien, 44093 Nantes cedex 1, France; CHU de Nantes, SIRIC-ILIAD, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France; Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France.
Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France; CHU de Grenoble, registre du cancer de l'Isère, pavillon E, CS 10217, 38043 Grenoble cedex 9, France.
Bull Cancer. 2019 Jul-Aug;106(7-8):617-634. doi: 10.1016/j.bulcan.2018.11.016. Epub 2019 Mar 2.
Incidence, mortality, survival and prevalence are key indicators to assess public health policies and estimate the needs of the population for cancer management. The aim of this article is to provide the more current estimates of these indicators, in line with the fifteenth operational objective of the 2014-2019 Cancer Plan "Collect data/Support Public Health".
Incidence and survival data came from cancer registries. Mortality data came from the French epidemiology center on medical causes of death. Prevalence was estimated by using incidence and survival estimates.
In metropolitan France in 2017, the estimated number of new cancer cases and cancer deaths was respectively 399,500 and 150,000. The most frequent cancers (breast, prostate) had highest net survivals: 78 and 84% at 10 years. Several cancers (including lung, liver and pancreatic cancers) had worse prognosis (5-year survival≤33%). In 2017, 1,396,000 men and 1,359,000 women had cancer in the previous 15 years, representing respectively 5.4% and 4.8% of the population aged 15 and over.
Despite the decrease of cancer mortality, the prognosis of some cancers remains poor and the cancer prevalence is high. These results highlight the need for intensifying the efforts already made in cancer prevention, diagnosis, and treatment and justify the interest in the post-cancer period.
发病率、死亡率、生存率和患病率是评估公共卫生政策以及估计人群癌症管理需求的关键指标。本文旨在根据2014 - 2019年癌症计划的第十五个业务目标“收集数据/支持公共卫生”，提供这些指标的最新估计值。
发病率和生存数据来自癌症登记处。死亡率数据来自法国医学死因流行病学中心。患病率通过发病率和生存估计值来估算。
2017年在法国本土，估计新增癌症病例数和癌症死亡数分别为399,500例和150,000例。最常见的癌症（乳腺癌、前列腺癌）净生存率最高：10年时分别为78%和84%。几种癌症（包括肺癌、肝癌和胰腺癌）预后较差（5年生存率≤33%）。2017年，在过去15年中有1,396,000名男性和1,359,000名女性患过癌症，分别占15岁及以上人口的5.4%和4.8%。
尽管癌症死亡率有所下降，但一些癌症的预后仍然很差，且癌症患病率很高。这些结果凸显了加强在癌症预防、诊断和治疗方面已做出努力的必要性，并证明了关注癌症后时期的意义。
